Phase 4 N=24 Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea
Papulopustular Rosacea
Primary: Rosacea Score on the Visual Analog Scale — 4.50; 4.52; 3.77; 3.06 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=36 The Quality of Life Study in Psoriasis Patients After Ustekinumab Treatment
Psoriasis
Primary: Improvement in Quality of Life Measured by Change in Psychological General Well-Being Scale (PGWB) at Week 36 From Baseline. — 23.97 units on a scale
Phase 4 N=343 Levetiracetam Versus Topiramate as Adjunctive Therapy to Evaluate Efficacy and Safety in Subjects With Refractory Partial Onset Seizures
Epilepsy
Primary: Percentage of Subjects Continuing the Allocated Investigational Treatment From the First Study Treatment Intake to Week 52, After the Beginning of Investigational…
Phase 4 N=51 Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects
Obesity
Primary: Change in iGFR (Glomerular Filtration Rate as Measured by Iohexol Clearance) From Baseline to End of Treatment — -14.92; 1.08 mL/min/1.73 m^2
Phase 4 N=128 CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
Chronic Myelogenous Leukemia in Chronic Phase
Primary: Number of Participants With Confirmed Complete Molecular Response (CMR) — 34 Participants
Phase 4 N=100 Comparing Outcomes for Prontosan Versus Normal Saline for Negative Pressure Wound Therapy With Instillation
Wound Infection
Primary: Number of Operating Room Visits — 2.5; 2.8 Operative Room Visits
Phase 4 N=103 Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)
HIV
Primary: Efficacy as Assessed by the Number of Participants Who Were HIV Positive at 6 Months — 0 participants
Phase 4 N=128 Atomoxetine, Placebo and Parent Management Training in Autism
Autism · Pervasive Development Disorder · Asperger's Disorder
Primary: Percentage of Participants Who Were Attention Deficit Hyperactivity Disorder (ADHD) Respondents — 45.2; 46.9; 29.0; 19.4 percentage of participants — p=0.47
Phase 4 N=112 Multicenter, Randomized, Open Label, Parallel Study to Evaluate the Efficacy & Safety of IVF-M HP Inj. vs. Menopur® Inj.
Infertility, Female
Primary: Number of Retrieved Oocytes — 13.14; 10.29 Oocytes
Phase 4 N=1,423 The Efficacy and Safety Study in Patients With Type 2 Diabetes Mellitus
Diabetes Mellitus, Non-Insulin-Dependent
Primary: Absolute Change From Baseline in Haemoglobin A1c (HbA1c) — -1.19; -1.59; -1.61 (%)
Phase 4 N=41 A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa
Anorexia Nervosa
Primary: Change in Eating Disorder Inventory-2 Drive for Thinness Subscale (DT) — 1.36; 3.93 units on a scale
Phase 4 N=57 Loop Diuretics Administration and Acute Heart Failure
Acute Heart Failure
Primary: Evaluation of Mean Urine Output Volume During the Infusion Period — 2505; 2140 mL — p=0.04
Phase 4 N=49 Evaluation of Ceftaroline Fosamil Versus a Comparator in Adult Subjects With Community-acquired Bacterial Pneumonia (CABP) With Risk for Methicillin-resistant Staphylococcus Aureus
Infections
Primary: Clinical Response at Study Day 4 in the Modified Intent-to-Treat (MITT) Population — 14; 8; 16; 8 participants
Phase 4 N=33 Valproate Dose Reduction and Its Clinical Evaluation by Introducing Lamotrigine in Japanese Women With Epilepsy - Single Arm, Multicenter, and Open-label Study
Epilepsy
Primary: Percentage of Participants Who Achieved Reduction in Daily VPA Dose — 60.6 Percentage of participants
Phase 4 N=62 A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations
Non-Squamous Non-Small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) — 12.846 Months